Vistin Pharma Q2 FY26 net profit drops 23.37% to MNOK 14.1; revenue falls 15.25% to MNOK 100

Reuters2026/08/20 05:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vistin Pharma posted Q2 revenue of NOK 100 million, down 15.25% year on year, despite an 8% rise in sales volume.
EBITDA fell 26.67% to NOK 22 million; the EBITDA margin was 22%.
Net profit slipped 23.37% to NOK 14.1 million; net debt stood at NOK 8 million at end-June.
First-half revenue declined 9% to NOK 212 million; first-half EBITDA dropped 18.33% to NOK 49 million.
CEO Magnus Tolleshaug cited 240 MT volume growth, customer onboarding in new regions, and manufacturing efforts to ramp up capacity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vistin Pharma ASA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200145OMX_____CNEWS_EN_GNW1001258365_en) on August 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vistin Pharma Q2 FY26 net profit drops 23.37% to MNOK 14.1; revenue falls 15.25% to MNOK 100

You may also like

Crypto prices